The role of CA 125 in epithelial ovarian carcinoma

Journal of B.U.ON.

Volumn 7, Issue 1, 2002, Pages 13-17

  Mandeville, H ^a   Rustin, G J S ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

CA 125; Ovarian carcinoma; Response; Tumour marker

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG RESPONSE; EARLY DIAGNOSIS; FOLLOW UP; HALF LIFE TIME; HUMAN; OVARY CARCINOMA; PATIENT MONITORING; PELVIS TUMOR; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TOXICITY;

EID: 0036253629     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Pros and cons of gynecologic tumor markers
2. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
3. Elevated serum concentrations of CA 125 in patients with advanced endometriosis
4. CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases
5. Tumor markers in the management of patients with ovarian cancer
6. Clinical validation of the new ESA-CA 125 II assay: Report of a European multicentre evaluation
7. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group
8. Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumour marker
9. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography
10. Screening for ovarian cancer: A pilot randomised controlled trial
11. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
12. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer
13. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer
14. CA 125 and survival in ovarian cancer: Preliminary communication
15. Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy
16. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group
17. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
18. Docetaxel in platinum-pretreated patients on behalf of the EORTC Early Clinical Trials Group
19. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study
20. The role of CA 125 as a tumour marker in ovarian cancer
21. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
22. Use of tumour markers in monitoring the course of ovarian cancer
23. New Guidelines to Evaluate the Response to Treatment in Solid Tumours (Ovarian Cancer)
24. Use of CA 125 to define progression of ovarian cancer in patients with persistently elevated levels